Chronic kidney disease
Conditions
Brief summary
The difference in the change in urine albumin-to-creatinine ratio (UACR), based on the average of two morning spot urine samples, between the two groups, measured from baseline to the end of both intervention periods (Intervention period I: semaglutide vs. control, followed by Intervention period II: additional finerenone for all participants).
Detailed description
Change in urine albumin-to-creatinine ratio from baseline to end of both intervention periods., Change in urine albumin-to-creatinine ratio from baseline to 20 weeks semaglutide treatment., Change in urine albumin-to-creatinine ratio from baseline to end of combination therapy (semaglutide followed by additional finerenone), compared to the change during semaglutide treatment alone.
Interventions
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the change in urine albumin-to-creatinine ratio (UACR), based on the average of two morning spot urine samples, between the two groups, measured from baseline to the end of both intervention periods (Intervention period I: semaglutide vs. control, followed by Intervention period II: additional finerenone for all participants). | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in urine albumin-to-creatinine ratio from baseline to end of both intervention periods., Change in urine albumin-to-creatinine ratio from baseline to 20 weeks semaglutide treatment., Change in urine albumin-to-creatinine ratio from baseline to end of combination therapy (semaglutide followed by additional finerenone), compared to the change during semaglutide treatment alone. | — |
Countries
Denmark
Outcome results
None listed